Freedom of Information request on how many people have either died from adverse reactions from the COVID-19 vaccines and the adverse reactions (FOI 21/1169)
Published 26 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-22-november-2021/freedom-of-information-request-on-how-many-people-have-either-died-from-adverse-reactions-from-the-covid-19-vaccines-and-the-adverse-reactions-foi-21
FOI 21/1169
25th November 2021
Dear,
Thank you for your email dated 27th October 2021, where you asked:
“I’m looking for how many people have either died from adverse reactions from what vaccine and what was it that they died of not covid 19 also I would like to know how many people and young people that been struck down from adverse reactions from the vaccines and what vaccine was it I need this information please.”
We can confirm that we do not hold this information as we do not collect complete fatality data. We suggest you contact the Office for National Statistics for death statistics, please find below contact details;
Email: info@ons.gov.uk
The MHRA publishes details of all suspected reactions reported in association with the COVID-19 vaccines, along with our assessment of the data on a weekly basis. Reports received through our Yellow Card scheme include some fatality reports and these can be viewed for each of the COVID vaccines by following the link below: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions
When considering the spontaneous data, it is important to be aware of the following points:
• A reported reaction does not necessarily mean it has been caused by the vaccine, only that the reporter had a suspicion it may have. Each year, millions of doses of routine vaccinations are given in the UK alone, and when any vaccine is administered to large numbers of people, some recipients will inevitably experience illness following vaccination. The fact that symptoms occur after use of a vaccine or medicine, and are reported via the Yellow Card Scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.
• It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different vaccines. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular medicine, and may be stimulated by promotion
and publicity about a drug. Reporting tends to be highest for newly introduced medicines during the first one to two years on the market and then falls over time.
• It is important to note that when submitting a Yellow Card, reporters may report the time to onset as the time when the first symptoms began, the time at which an admission occurred or a diagnosis. The MHRA consider all ADR reports in our ongoing analysis regardless of time to onset and look at a range of risk windows in our statistical analysis; we never exclude a case.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team
Vigilance and Risk Management of Medicines Division